For comments, suggestions
Created with Raphaël 2.1.0 18.09.2018 Filing date 31.03.2020 Validation fee payment 31.08.2020 (A1) Patent application published 10.05.2025 AGEPI application filing date 31.07.2025 (T2) Translation of the validated European patent 25.10.2025 18.09.2026 Valid until 19.09.2027 Renewal fee to be paid until 18.09.2038 Patent will expire on

Patent in force


(210)Number of the EPO application18783228
(220)Filing date of the EPO application2018.09.18
(80)EPO patent specification publication (B)EPB nr. 10/2025, 2025.03.05
(110)EPO patent number3684333
(11)Number of the documentMD 3684333 T2
(21)Number of the applicatione 2020 0771
(71)Name(s) of applicant(s), code of the countryNEUROCRINE BIOSCIENCES, INC., US;
(72)Name(s) of inventor(s), code of the countryMOORE Richard Alexander Jr., US;
MCCLELLAND Gregory A., US;
O'BRIEN Christopher F., US;
(73)Name(s) of owner(s), code of the countryNEUROCRINE BIOSCIENCES INC., US;
(54)Title of the inventionHigh dosage valbenazine formulation and compositions, methods, and kits related thereto
(13)Kind-of-document code T2
(51)International Patent Classification A61K 9/00 (2006.01.01); A61K 47/12 (2006.01.01); A61K 47/26 (2006.01.01); A61K 47/36 (2006.01.01); A61K 47/38 (2006.01.01); A61K 9/48 (2006.01.01); A61K 31/4745 (2006.01.01); A61P 25/00 (2006.01.01)
(19)CountryUS
(41)Date of publication of the application2020.08.31
(49)Date of publication of the translation of the validated European patent specification2025.07.31
(30)Priority201762561629 P, 2017.09.21, US; 201762564951 P, 2017.09.28, US
(74)Patent attorney(Procedură) CORCODEL Angela, Bd. Ştefan cel Mare nr. 134, Chişinău, Republica Moldova
(86)International applicationPCT/US2018/051579, 2018.09.18
(87)International publicationWO 2019/060322, 2019.03.28
Up
/Inventions/details/3684333